<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02078492</url>
  </required_header>
  <id_info>
    <org_study_id>2014-01-19</org_study_id>
    <nct_id>NCT02078492</nct_id>
  </id_info>
  <brief_title>A Prospective Randomized Double-Blind Trial Comparing 3 Doses of Intravenous Ketorolac for Pain Management</brief_title>
  <official_title>A Prospective Randomized Double-Blind Trial Comparing 3 Doses of Intravenous Ketorolac for Pain Management in the Emergency Department&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antonios Likourezos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimonides Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Intravenous administration of Ketorolac in a dose of 10 mg is as effective in
      treating severe acute pain in patients presenting to the ED as 15 mg and 30 mg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) that is widely used
      in the Emergency Department (ED) for the treatment of moderate-to-severe pain. Ketorolac is
      available in both oral and parenteral forms and possess significant analgesic potency.
      However, ketorolac provides few advantages over other currently available analgesics and its
      use is limited by a virtue of having an &quot;analgesic ceiling&quot; with the dose being 10mg as well
      as having a range of severe side effects, of which gastrointestinal hemorrhage is most
      concerning.The concept of an analgesic ceiling is that doses beyond this value (10mg) do not
      provide additional analgesia and do contribute to side effects. In spite of this, the
      majority of research conducted on ketorolac in the ED and recommendations in Tintinalli's
      Emergency Medicine Textbook advocating for use of three-to-six fold higher dosages.

      Hypothesis: Intravenous administration of Ketorolac in a dose of 10 mg is as effective in
      treating severe acute pain in patients presenting to the ED as 15 mg and 30 mg.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Score at 30 Minutes</measure>
    <time_frame>30 minutes</time_frame>
    <description>Pain score of each group at 30 minutes. The Numeric Rating Pain (NRS) scale was used for the study. The NRS ranges from 0 (no pain) to 10 (very severe pain). A score of 5 is moderate pain. The higher the pain score the higher the pain severity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Effect of Dizziness</measure>
    <time_frame>120 minutes</time_frame>
    <description>the number of study patients who reported having dizziness after administration of medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Effect of Nausea</measure>
    <time_frame>120 minutes</time_frame>
    <description>The number of study patients who reported nausea after administration of medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Effect of Headache</measure>
    <time_frame>120 minutes</time_frame>
    <description>The number of study patients who reported headache after administration of medication</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Group 1 - 10 mg of Ketorolac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be administered 10 mg of Ketorolac for pain relief.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - 15mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be administered 15mg of Ketorolac.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 - 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive 30mg of Ketorolac as a part of standard care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10 mg of Ketorolac</intervention_name>
    <description>Patients will receive 10 mg of Ketorolac for pain control.</description>
    <arm_group_label>Group 1 - 10 mg of Ketorolac</arm_group_label>
    <other_name>Toradol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>15 mg of Ketorolac</intervention_name>
    <description>Patients will receive 15mg of Ketorolac for pain control.</description>
    <arm_group_label>Group 2 - 15mg</arm_group_label>
    <other_name>Toradol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>30 mg of Ketorolac</intervention_name>
    <description>Patients will receive 30mg of Ketorolac for pain control.</description>
    <arm_group_label>Group 3 - 30mg</arm_group_label>
    <other_name>Toradol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Severe flank and abdominal pain, severe musculoskeletal pain (traumatic and non-traumatic
        in origin), headache, dental pain.

        Exclusion Criteria:

        Age &gt;65, Active Peptic Ulcer disease, Acute Gastrointestinal Hemorrhage, Known Hx of Renal
        or Hepatic insufficiency, Hx of allergies to NSAIDS.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergey Motov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Attending</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Catapano MS. The analgesic efficacy of ketorolac for acute pain. J Emerg Med. 1996 Jan-Feb;14(1):67-75. Review.</citation>
    <PMID>8655940</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2014</study_first_submitted>
  <study_first_submitted_qc>March 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2014</study_first_posted>
  <results_first_submitted>January 3, 2017</results_first_submitted>
  <results_first_submitted_qc>February 25, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 10, 2017</results_first_posted>
  <last_update_submitted>February 25, 2017</last_update_submitted>
  <last_update_submitted_qc>February 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Maimonides Medical Center</investigator_affiliation>
    <investigator_full_name>Antonios Likourezos</investigator_full_name>
    <investigator_title>Research Manager</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1 - 10 mg of Ketorolac</title>
          <description>Subjects will be administered 10 mg of Ketorolac for pain relief.
10 mg of Ketorolac: Patients will receive 10 mg of Ketorolac for pain control.</description>
        </group>
        <group group_id="P2">
          <title>Group 2 - 15mg</title>
          <description>Subjects will be administered 15mg of Ketorolac.
15 mg of Ketorolac: Patients will receive 15mg of Ketorolac for pain control.</description>
        </group>
        <group group_id="P3">
          <title>Group 3 - 30mg</title>
          <description>Subject will receive 30mg of Ketorolac as a part of standard care.
30 mg of Ketorolac: Patients will receive 30mg of Ketorolac for pain control.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="80"/>
                <participants group_id="P3" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="80"/>
                <participants group_id="P3" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1 - 10 mg of Ketorolac</title>
          <description>Subjects will be administered 10 mg of Ketorolac for pain relief.
10 mg of Ketorolac: Patients will receive 10 mg of Ketorolac for pain control.</description>
        </group>
        <group group_id="B2">
          <title>Group 2 - 15mg</title>
          <description>Subjects will be administered 15mg of Ketorolac.
15 mg of Ketorolac: Patients will receive 15mg of Ketorolac for pain control.</description>
        </group>
        <group group_id="B3">
          <title>Group 3 - 30mg</title>
          <description>Subject will receive 30mg of Ketorolac as a part of standard care.
30 mg of Ketorolac: Patients will receive 30mg of Ketorolac for pain control.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
            <count group_id="B2" value="80"/>
            <count group_id="B3" value="80"/>
            <count group_id="B4" value="240"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.5" spread="12.1"/>
                    <measurement group_id="B2" value="40.1" spread="12.1"/>
                    <measurement group_id="B3" value="38.8" spread="11.6"/>
                    <measurement group_id="B4" value="40.2" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="132"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Score at 30 Minutes</title>
        <description>Pain score of each group at 30 minutes. The Numeric Rating Pain (NRS) scale was used for the study. The NRS ranges from 0 (no pain) to 10 (very severe pain). A score of 5 is moderate pain. The higher the pain score the higher the pain severity.</description>
        <time_frame>30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - 10 mg of Ketorolac</title>
            <description>Subjects will be administered 10 mg of Ketorolac for pain relief.
10 mg of Ketorolac: Patients will receive 10 mg of Ketorolac for pain control.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - 15mg</title>
            <description>Subjects will be administered 15mg of Ketorolac.
15 mg of Ketorolac: Patients will receive 15mg of Ketorolac for pain control.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - 30mg</title>
            <description>Subject will receive 30mg of Ketorolac as a part of standard care.
30 mg of Ketorolac: Patients will receive 30mg of Ketorolac for pain control.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score at 30 Minutes</title>
          <description>Pain score of each group at 30 minutes. The Numeric Rating Pain (NRS) scale was used for the study. The NRS ranges from 0 (no pain) to 10 (very severe pain). A score of 5 is moderate pain. The higher the pain score the higher the pain severity.</description>
          <units>pain score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.14" spread="2.70"/>
                    <measurement group_id="O2" value="5.05" spread="2.56"/>
                    <measurement group_id="O3" value="4.81" spread="2.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Effect of Dizziness</title>
        <description>the number of study patients who reported having dizziness after administration of medication.</description>
        <time_frame>120 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - 10 mg of Ketorolac</title>
            <description>Subjects will be administered 10 mg of Ketorolac for pain relief.
10 mg of Ketorolac: Patients will receive 10 mg of Ketorolac for pain control.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - 15mg</title>
            <description>Subjects will be administered 15mg of Ketorolac.
15 mg of Ketorolac: Patients will receive 15mg of Ketorolac for pain control.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - 30mg</title>
            <description>Subject will receive 30mg of Ketorolac as a part of standard care.
30 mg of Ketorolac: Patients will receive 30mg of Ketorolac for pain control.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Effect of Dizziness</title>
          <description>the number of study patients who reported having dizziness after administration of medication.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Effect of Nausea</title>
        <description>The number of study patients who reported nausea after administration of medication</description>
        <time_frame>120 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - 10 mg of Ketorolac</title>
            <description>Subjects will be administered 10 mg of Ketorolac for pain relief.
10 mg of Ketorolac: Patients will receive 10 mg of Ketorolac for pain control.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - 15mg</title>
            <description>Subjects will be administered 15mg of Ketorolac.
15 mg of Ketorolac: Patients will receive 15mg of Ketorolac for pain control.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - 30mg</title>
            <description>Subject will receive 30mg of Ketorolac as a part of standard care.
30 mg of Ketorolac: Patients will receive 30mg of Ketorolac for pain control.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Effect of Nausea</title>
          <description>The number of study patients who reported nausea after administration of medication</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Effect of Headache</title>
        <description>The number of study patients who reported headache after administration of medication</description>
        <time_frame>120 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - 10 mg of Ketorolac</title>
            <description>Subjects will be administered 10 mg of Ketorolac for pain relief.
10 mg of Ketorolac: Patients will receive 10 mg of Ketorolac for pain control.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - 15mg</title>
            <description>Subjects will be administered 15mg of Ketorolac.
15 mg of Ketorolac: Patients will receive 15mg of Ketorolac for pain control.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - 30mg</title>
            <description>Subject will receive 30mg of Ketorolac as a part of standard care.
30 mg of Ketorolac: Patients will receive 30mg of Ketorolac for pain control.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Effect of Headache</title>
          <description>The number of study patients who reported headache after administration of medication</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The main hypothesis was that there would be equivalence of dose effect across the three groups at every time point, and the primary comparison consisted of the pain assessment at 30 minutes.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>We assumed a minimal clinically significant difference (MCSD) of 1.3 between the three ketorolac groups at the 30-minute pain assessment and a standard deviation of 3.0. A power analysis determined that a sample of 78 subjects per group provided at least 80% power to detect an MCSD of at least 1.3 at 30 minutes with α=0.05.</non_inferiority_desc>
            <p_value>.783</p_value>
            <method>ANOVA</method>
            <method_desc>2 degrees of freedom</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1 - 10 mg of Ketorolac</title>
          <description>Subjects will be administered 10 mg of Ketorolac for pain relief.
10 mg of Ketorolac: Patients will receive 10 mg of Ketorolac for pain control.</description>
        </group>
        <group group_id="E2">
          <title>Group 2 - 15mg</title>
          <description>Subjects will be administered 15mg of Ketorolac.
15 mg of Ketorolac: Patients will receive 15mg of Ketorolac for pain control.</description>
        </group>
        <group group_id="E3">
          <title>Group 3 - 30mg</title>
          <description>Subject will receive 30mg of Ketorolac as a part of standard care.
30 mg of Ketorolac: Patients will receive 30mg of Ketorolac for pain control.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sergey Motov</name_or_title>
      <organization>Maimonides Medical Center</organization>
      <phone>718-283-8693</phone>
      <email>smotov@maimonidesmed.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

